This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2015 May;5(5):OF1.

doi: 10.1158/2159-8290.CD-NB2015-042. Epub 2015 Apr 2.

Nivolumab approved for lung cancer

No authors listed

PMID: 25835401
DOI: 10.1158/2159-8290.CD-NB2015-042

Nivolumab approved for lung cancer

No authors listed. Cancer Discov. 2015 May.

. 2015 May;5(5):OF1.

doi: 10.1158/2159-8290.CD-NB2015-042. Epub 2015 Apr 2.

PMID: 25835401
DOI: 10.1158/2159-8290.CD-NB2015-042

No abstract available

PubMed Disclaimer

Similar articles

The FDA approves drugs for colorectal cancer, lung cancer.
[No authors listed] [No authors listed] FDA Consum. 2007 Jan-Feb;41(1):5. FDA Consum. 2007. PMID: 17354284 No abstract available.
Off-label uses of bevacizumab: breast and lung cancer indications.
[No authors listed] [No authors listed] Technol Eval Cent Assess Program Exec Summ. 2006 Oct;21(8):1-4. Technol Eval Cent Assess Program Exec Summ. 2006. PMID: 17061398 No abstract available.
Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
Pennell NA. Pennell NA. Semin Oncol. 2015 Oct;42 Suppl 2:S3-10. doi: 10.1053/j.seminoncol.2015.09.016. Epub 2015 Sep 11. Semin Oncol. 2015. PMID: 26477472 Review.
Monoclonal antibody approved for metastatic breast cancer.
[No authors listed] [No authors listed] Oncology (Williston Park). 1998 Dec;12(12):1727. Oncology (Williston Park). 1998. PMID: 9874846 No abstract available.
Approved monoclonal antibodies for cancer therapy.
Boyiadzis M, Foon KA. Boyiadzis M, et al. Expert Opin Biol Ther. 2008 Aug;8(8):1151-8. doi: 10.1517/14712598.8.8.1151. Expert Opin Biol Ther. 2008. PMID: 18613766 Review.

See all similar articles

Cited by

The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.
Talebian Yazdi M, van Riet S, van Schadewijk A, Fiocco M, van Hall T, Taube C, Hiemstra PS, van der Burg SH. Talebian Yazdi M, et al. Oncotarget. 2016 Jan 19;7(3):3477-88. doi: 10.18632/oncotarget.6506. Oncotarget. 2016. PMID: 26658106 Free PMC article.
The role of radiology in the evaluation of the immunotherapy efficacy.
Calandri M, Solitro F, Angelino V, Moretti F, Veltri A. Calandri M, et al. J Thorac Dis. 2018 May;10(Suppl 13):S1438-S1446. doi: 10.21037/jtd.2018.05.130. J Thorac Dis. 2018. PMID: 29951295 Free PMC article. Review.
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
Adashek JJ, Kato S, Ferrara R, Lo Russo G, Kurzrock R. Adashek JJ, et al. Oncologist. 2020 Feb;25(2):94-98. doi: 10.1634/theoncologist.2019-0636. Epub 2019 Nov 20. Oncologist. 2020. PMID: 32043794 Free PMC article.
Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.
Mayor M, Yang N, Sterman D, Jones DR, Adusumilli PS. Mayor M, et al. Eur J Cardiothorac Surg. 2016 May;49(5):1324-33. doi: 10.1093/ejcts/ezv371. Epub 2015 Oct 29. Eur J Cardiothorac Surg. 2016. PMID: 26516195 Free PMC article. Review.
Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade.
Chuang YC, Tseng JC, Huang LR, Huang CM, Huang CF, Chuang TH. Chuang YC, et al. Front Immunol. 2020 May 29;11:1075. doi: 10.3389/fimmu.2020.01075. eCollection 2020. Front Immunol. 2020. PMID: 32547560 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Medical
- MedlinePlus Health Information